ABCL News and Press, AbCellera Biologics Inc. From 04/06/23

AbCellera (Nasdaq: ABCL) will announce its first quarter 2023 financial results on Thursday, May 4, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that...

2023-04-04 22:01:45 ET Summary Baker Brothers’ 13F portfolio value increased from $15.27B to $16.65B this quarter. Replimune Group stake was substantially increased this quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to alm...

2023-04-01 05:17:00 ET Summary Most readers follow my work for the extensive writing I have done referencing my aggressive growth portfolio. However, the vast majority of my net worth is held in my all-weather portfolio. In this article, I would like to draw back the curtain on my...

2023-03-24 13:54:41 ET Summary AbCellera's monstrous 2020 IPO raised >$480m. The company is pledging to discover promising antibodies for its clients and bring them to the clinic faster than anybody else. For its work, AbCellera earns milestone payments if the molecules go ...

2023-03-23 17:06:11 ET Summary Today, we take a deeper look at AbCellera Biologics whose Covid revenue stream is fading fast as the pandemic ends. However, its core business continues to show progress, the shares are well liked by analyst firms and had heavy insider buying in 2022...

2023-03-22 10:06:44 ET AbCellera Biologics ( NASDAQ: ABCL ) will work with RQ Bio to dentify optimal clinical candidates for up to three infectious disease targets chosen by the latter. The disease areas will include influenza and cytomegalovirus (CMV). Terms call ...

AbCellera (Nasdaq: ABCL) and RQ Bio announced today that they have entered into a strategic collaboration to identify optimal clinical candidates for up to three infectious disease targets selected by RQ Bio, including influenza and cytomegalovirus (CMV). The partnership aims to provide lon...

AbCellera (Nasdaq: ABCL) today announced that it will present at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023, at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). A live audio webcast of the presentation may be accessed through a link that will be posted on AbCel...

Image source: The Motley Fool. AbCellera Biologics (NASDAQ: ABCL) Q4 2022 Earnings Call Feb 21, 2023 , 5:00 p.m. ET Operator Continue reading For further details see: AbCellera Biologics (ABCL) Q4 2022 Earnings Call Transcript

The following slide deck was published by AbCellera Biologics Inc. in conjunction with their 2022 Q4 earnings call. For further details see: AbCellera Biologics Inc. 2022 Q4 - Results - Earnings Call Presentation